Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
881-900 of 991 trials

Infant Immunity to Whooping Cough: Maternal Vaccination Study

We are studying how vaccines given to pregnant women affect their infants' immunity to whooping cough. Our goal is to find out what factors influence the transfer of protective antibodies from mothers to their babies.

Whooping Cough>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsInfectious DiseasesInternal Medicine

Long COVID: Fibroblast Activity Study with [68Ga]FAPI PET/CT

We are investigating if patients with ongoing long COVID symptoms have higher fibroblast activity than those who have recovered. This may help us understand the underlying causes of long-term health issues after COVID-19.

Long COVIDConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Essential Tremor: BP1.4979 Treatment Study

We are testing a new medication, BP1.4979, for adults with essential tremor to see if it helps reduce symptoms and improve quality of life. The study will also check how safe the treatment is for patients.

Essential Tremor1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Premature Ejaculation: BP1.4979 Study

We are testing a new medication for adult men with primary premature ejaculation to see if it improves ejaculatory control and sexual satisfaction compared to a placebo.

Premature Ejaculation3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryUrology

Opioid-Induced Respiratory Depression: Naloxone and Nalmefene Study

We are studying how well naloxone and nalmefene can reverse breathing problems caused by opioids in both new and long-term users. This research aims to improve treatment options for respiratory depression in real-life settings.

Healthy VolunteersOpioid Use Disorder>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineOtolaryngologyPulmonology

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder

We are studying whether a high dose of psilocybin can help reduce heavy drinking in people with severe alcohol use disorder during inpatient rehabilitation. This trial also examines the safety and effects on mental health and cognitive function.

Severe Alcohol Use Disorder6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPsychiatry

Lung Cancer: RMC-6236 vs. Docetaxel

We are studying a new treatment for patients with advanced lung cancer who have RAS mutations. The goal is to see if RMC-6236 works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Moderate Atopic Dermatitis: Ruxolitinib Cream for Kids

We are studying a new cream for children and adolescents aged 6 to under 18 with moderate atopic dermatitis who haven't had success with other treatments. The trial will assess how well it works and its safety.

Atopic Dermatitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Cancer Anorexia: ART27.13 Cannabinoid Study

We are testing a new synthetic cannabinoid to see if it helps patients with cancer gain weight and improve appetite. The study also looks at the safety and quality of life for participants.

Cancer Anorexia3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Plozasiran for Severe Hypertriglyceridemia: SHASTA-5 Study

We are studying whether plozasiran can help adults with severe hypertriglyceridemia reduce their triglyceride levels and lower the risk of acute pancreatitis. The trial also looks at the treatment's safety and how it affects patients' overall health.

High Triglycerides>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Prolonged Grief Disorder: PEX010 Treatment

We are testing a new treatment called PEX010 for people experiencing prolonged grief disorder. The study aims to see if it can significantly reduce grief symptoms and explore the effects of self-touch.

Prolonged Grief Disorder≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Polymyalgia Rheumatica: Hydrocortisone Supplement Study

We are investigating whether supplemental hydrocortisone helps improve quality of life for patients with polymyalgia rheumatica or giant cell arteritis experiencing adrenal insufficiency. The focus is on how it affects fatigue during stress.

Glucocorticoid Induced Adrenal Insufficiency6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Crohn’s Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn’s disease. The goal is to see if it helps achieve remission and improve symptoms compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Uncontrolled Asthma: GSK5784283 Treatment Study

We are testing a new antibody treatment for adults with uncontrolled asthma to see if it helps improve lung function and asthma control compared to a placebo.

Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonology

Idiopathic Pulmonary Fibrosis: CAL101 Treatment Study

We are studying whether CAL101 can improve lung function in patients with idiopathic pulmonary fibrosis compared to a placebo. The trial also looks at the safety of this new treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Transthyretin Amyloidosis with Cardiomyopathy: Vutrisiran Study

We are evaluating the safety and effectiveness of vutrisiran in patients with transthyretin amyloidosis and heart issues. This study includes those continuing treatment or switching from another medication.

Cardiac Amyloidosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Acute Myeloid Leukemia: L-Annamycin with Cytarabine

We are studying a new treatment combining L-Annamycin with Cytarabine for adults with difficult-to-treat acute myeloid leukemia. The goal is to see if this combination can help achieve remission better than a placebo.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Batoclimab Study

We are studying the long-term safety and tolerability of batoclimab in adults with CIDP. This trial aims to see how well the medication works for managing symptoms over time.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Lung Cancer Treatment: Divarasib and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if this new approach improves survival and quality of life compared to standard treatments.

Advanced Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology